Trials / Completed
CompletedNCT04175522
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
A Phase 2a, Prospective, Open-label, Single-arm, Single Center, Proof of Concept Study to Evaluate the Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunoglobulin G | IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously. |
Timeline
- Start date
- 2019-11-20
- Primary completion
- 2020-06-11
- Completion
- 2020-06-11
- First posted
- 2019-11-25
- Last updated
- 2020-06-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04175522. Inclusion in this directory is not an endorsement.